Jarushka Naidoo: Perioperative Nivolumab in Stage IIA-IIIB NSCLC

Jarushka Naidoo shared on X/Twitter:

”Ph III CM77T trial at NEJM: Perioperative Nivolumab in Stage IIA-IIIB NSCLC:

• Neoadjuvant nivolumab + chemotherapy for 4 cycles + 1-year adjuvant nivolumab vs neoadjuvant chemotherapy for 4 cycles + 1-year adjuvant placebo.
• EFS HR 0.58 (p<0.001), pCR 25.3% vs 4.7% favoring nivolumab + chemotherapy.
• g3 + TRAEs in 32.5% vs 25.2%.”

Source: Jarushka Naidoo/X

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials. She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.